BOEHRINGER-INGELHEIM
The European Commission (EC) granted a conditional marketing authorization for Boehringer Ingelheim’s spesolimab as first in class treatment for GPP flares in adults.1 Spesolimab is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP.2, 4-7
“The symptoms of GPP are devastating and cause immense pain as well as hospitalization during a flare. Increased GPP awareness that leads to accurate and faster diagnosis is one important step to improving the quality of life for people living with GPP,” said Frida Dunger Johnsson, Executive Director, IFPA. “Now with a specifically developed treatment, people living with GPP can be offered a new lease of life by effectively managing the impact of GPP flares.”
“We are delighted to be able to bring this much needed treatment to patients with GPP, whose options were incredibly limited until this year. This approval marks another significant milestone in the continued development of spesolimab in neutrophilic skin diseases which we are investigating in further clinical trials” commented Carinne Brouillon, Member of the Board of Managing Directors, responsible for Human Pharma, Boehringer Ingelheim. “Today’s news marks the first of what we hope will be a number of new treatment options from our accelerated late-stage portfolio with the potential to transform the lives of people for generations to come.”
The EC’s conditional approval of spesolimab is based on results from the pivotal EFFISAYIL® 1 Phase II clinical trial.2 In the 12-week trial, patients experiencing a GPP flare were treated with spesolimab or placebo. Most patients at the outset of the trial had a moderate or severe pustulation of the skin. After one week, 54% of patients treated with a single dose of spesolimab showed no visible pustules compared to placebo (6%).2 Adverse events were reported in 66% of patients treated with spesolimab and 56% of those receiving placebo after one week.2 Infections were reported by 17% and 6% of patients in the spesolimab and placebo groups respectively (at week one).2 Serious adverse events were reported in 6% of patients treated with spesolimab (at week one).2
People living with GPP often do not receive a correct or timely diagnosis and may have their symptoms identified as other forms of psoriasis. A Global Delphi Consensus Project classified GPP as phenotypically, genetically, immunologically and histopathologically distinct from psoriasis vulgaris / plaque psoriasis based on a systematic literature review.3 The growing list of regulatory approvals for spesolimab for the treatment of GPP flares underlines that the Delphi panel’s vision of improved diagnosis and treatment for people with GPP is increasingly achievable.
For the full press release and link to ‘Notes to Editors’ please click here:
Additional information
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005586/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
10-Year Partnership Between ISN® and Yara International Enhances Ongoing Commitment to Contractor Safety14.5.2025 10:00:00 CEST | Press release
The global leader in crop nutrition continues to leverage ISNetworld® solutions to advance contractor compliance and safety practices ISN, the global leader in contractor and supplier information management services, celebrates 10 years of partnership with the European division of Yara International (Yara), a leading provider of crop nutrition and sustainable agricultural solutions. After a successful implementation in the Americas, Yara adopted ISNetworld across its European sites in 2015, expanding its use of the contractor management platform, streamlining processes, and improving operational efficiency. “Over the past decade, ISN has been instrumental to Yara’s contractor management processes in Norway and the Netherlands," said Steinar Bjelland, Procurement Manager at Yara. "Leveraging ISNetworld tools and services such as RAVS 360™ and acknowledgment form tracking, along with ISN’s multilingual support, has helped Yara optimise compliance, improve communication, and effectively a
Ares Management Opens Milan Office14.5.2025 10:00:00 CEST | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the opening of a new office in Milan, the firm’s latest office in Europe. The office will enhance Ares’ access to the Italian market, and its ability to raise and invest capital across its strategies, particularly within its European Direct Lending business, as well as the Wealth Management and European Real Estate platforms. This latest opening underscores Ares’ commitment to a highly localized approach to investing in Europe, which the firm entered in 2007 through the opening of a London office, followed by Paris, Frankfurt and Stockholm in 2009 and, most recently, Amsterdam and Madrid in 2019. Across its investment strategies, including European Direct Lending and European Real Estate, Ares has deployed over €1.6 billion to support Italian businesses and assets, as of March 31, 2025, and Ares expects to accelerate this activity in the coming years. Tyrone Cooney, Partn
Intelsat, Cubic³ Complete Vehicle Satellite Connectivity Test, Advancing Ubiquitous Connectivity Vision14.5.2025 09:00:00 CEST | Press release
Groundbreaking Memorandum of Understanding brings seamless, global connectivity closer to reality for connected cars, agriculture, and heavy machinery vehicles Intelsat and Cubic³ have successfully completed a critical vehicle satellite connectivity test, marking a significant milestone in their joint mission to create a seamless connectivity service for all types of vehicles. The test demonstrated successful integration between Intelsat satellites and Cubic³’s software platform, showcasing how terrestrial and non-terrestrial networks can seamlessly link to deliver always-on connectivity regardless of location. “Our Memorandum of Understanding and successful test brings us closer to our vision of truly ubiquitous connectivity,” said Bruno Fromont, Intelsat Chief Technology Officer. “By combining Intelsat’s satellite expertise with Cubic³’s innovative connectivity platform, we’re creating solutions that will keep vehicles connected anywhere in the world, enabling critical functions from
Norli Liv & Pension Modernizes Investment Operations with Clearwater Analytics14.5.2025 09:00:00 CEST | Press release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced that Danish pension provider, Norli Liv & Pension, part of the Norli group, has partnered with Clearwater to modernize its investment accounting, reporting and compliance operations. Clearwater will provide Norli with a single, consolidated view of all in-house and outsourced chief investment officer (OCIO) managed holdings across its public and private asset classes—enhancing investment transparency and empowering better, faster decision-making. The platform will also support regulatory compliance through automated workflows and robust, audit-ready reporting. By moving to Clearwater’s single instance, multi-tenant platform, Norli Liv & Pension will eliminate multiple legacy platforms, reduce manual work and accelerate its monthly close. The platform’s “single pane of glass” view will provide users across departments with unified access to accurate, timely data and a
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)14.5.2025 08:14:00 CEST | Press release
Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment options Phase II data show potential of efimosfermin to reverse liver fibrosis, demonstrated in metabolic dysfunction-associated steatohepatitis (a form of SLD) Unique properties offer potential for efimosfermin to be a new standard-of-care Significantly expands GSK’s hepatology pipeline aimed at addressing steatotic and viral drivers of liver disease, offering multiple development options and potential first launch in 2029 GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, today announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progress
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom